Tech Company Financing Transactions
Ceptaris Therapeutics Funding Round
On 11/26/2007, Ceptaris Therapeutics landed $14.5 million in Series C financing from Vivo Capital, Palo Alto Investors and private investors.
Transaction Overview
Company Name
Announced On
11/26/2007
Transaction Type
Venture Equity
Amount
$14,500,000
Round
Series C
Investors
Vivo Capital (Lead Investor) (Albert Cha)
Proceeds Purpose
The financing will support the ongoing clinical development program for Clearazide(TM), a topically delivered cytotoxic agent for the treatment of cutaneous T-cell lymphoma (CTCL) that is currently in pivotal clinical studies. The funding will also position Yaupon to pursue neuropsychiatric indications such as Attention Deficit Disorder (ADD) and Tourette's syndrome for Lobeline, a dopamine modulating agent that is currently in phase 2 trials for methamphetamine addiction. The funding will also help to bring Yaupon's pain programs into clinical stage development.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
101 Lindenwood Dr. 400
Malvern, PA 19355
USA
Malvern, PA 19355
USA
Phone
Website
Email Address
Overview
Ceptaris Therapeutics Inc., a privately held, specialty pharmaceutical company, is developing a proprietary formulation of mechlorethamine gel for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Steve Tullman
Chief Medical Officer
Jeffrey Wilkins
Chief Operating Officer
Douglas Gssl
VP - Bus. Development
Evan Dick
VP - General Counsel
Kamil Ali-Jackson
VP - Operations
Jeffrey Shaver
VP - R & D
Timothy Henkel
Browse more venture capital transactions:
Prev: 11/26/2007: Carbylan Therapeutics venture capital transaction
Next: 11/26/2007: Vixxi Solutions venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs